- FluMist® Trivalent is the first and only intranasal, needle-free influenza vaccine approved in Singapore by the Health Sciences Authority, expanding access to vaccination options for eligible individuals aged 2 to 49 years.1,2*
- Aligned with the World Health Organization’s recommendations, FluMist® Trivalent offers protection against influenza A (H1N1, H3N2) and B/Victoria strains.1,3
Singapore, 18 November 2025—AstraZeneca’s FluMist® Trivalent (Influenza Vaccine Live, Intranasal) is now available in Singapore for the prevention of influenza disease caused by influenza virus subtypes A and B.1 Approved by the Health Sciences Authority (HSA) for use in individuals aged 2 to 49 years, FluMist® Trivalent is the first and only intranasal, needle-free influenza vaccine now available in Singapore.1,2*
Singapore now joins other key markets, including the United Kingdom and the United States, as one of the latest countries in Asia where the vaccine has been approved for use, marking a significant milestone in expanding vaccine options for patients.
A new option in the fight against seasonal influenza
Influenza viruses circulate year-round in Singapore, with seasonal peaks typically observed from May to August and December to March.4 While influenza is often perceived as a mild illness, severe cases can lead to pneumonia, hospitalisation, and even death, particularly among vulnerable groups such as young children, older adults, and individuals with underlying health conditions.4
Vaccination remains an effective way to prevent influenza and its complications.5,6 Clinical studies have shown that influenza vaccination can reduce the severity of illness among those who contract the virus, helping to lower the risk of serious outcomes.6
“Influenza continues to be an important health priority, and AstraZeneca is steadfast in our commitment to expanding access to innovative, patient-focused solutions,” said Ms Suyeon Kim, Country President, AstraZeneca Singapore. “We’re proud to introduce Singapore’s first intranasal, needle-free influenza vaccine. FluMist® Trivalent is designed to improve the vaccination experience, supporting Singapore’s efforts to protect more people from potentially serious flu complications and contributing to better public health outcomes.”
Innovating to improve vaccination experience
As a live attenuated intranasal vaccine, FluMist® Trivalent provides protection against influenza A (H1N1, H3N2) and B/Victoria lineages. This is in alignment with the World Health Organization’s latest recommendation that the inclusion of B/Yamagata lineage antigen is no longer required in seasonal influenza vaccines.1,3
Administered as a simple nasal spray, the vaccine offers an immunisation route that may enhance acceptance among eligible individuals who are hesitant about vaccination.7-10
“In a time when vaccine fatigue and hesitancy are increasing, having a needle-free option like FluMist® Trivalent can be a game-changer for public health,” said Dr Leong Hoe Nam, Infectious Disease Specialist at Mount Elizabeth Novena Hospital. “Removing the barrier of needles could significantly increase vaccination uptake across the population. When more people are protected, we can better safeguard our most vulnerable and ease the burden of serious flu complications on our healthcare system. It is an innovation that has the potential to shift our vaccination rates and strengthen Singapore’s resilience against seasonal flu outbreaks.”
About FluMist® Trivalent
FluMist® Trivalent (Influenza Vaccine Live, Intranasal) is indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A (H1N1, H3N2) and B/Victoria.1 The vaccine is for intranasal administration only.1
The most common side effects observed include runny or stuffy nose, sore throat in adults, and mild fever in young children.1
Joining other key markets, including the United Kingdom and the United States, FluMist® Trivalent has been approved in Singapore and selected Asian markets for use. Regulatory reviews are ongoing in other Asia-Pacific markets.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Media Contacts
Muse & Motif for AstraZeneca
Wang Tian Tian
+65 9853 8792
Email: tiantian@museandmotif.com
Muse & Motif for AstraZeneca
Joscelin Kwek
+65 9745 4250
Email: joscelin@museandmotif.com
Approval Code: SG-10212 FLU_11/2025
References
*As of November 18, 2025
- FluMist Trivalent Influenza Intranasal Vaccine. Singapore Prescribing Information. August 2025.
- Singapore Health Sciences Authority. New drug approvals – July 2025. Available at www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2025. Accessed on November 17, 2025.
- World Health Organization. Recommended composition of influenza virus vaccines for use in the 2025-2026 northern hemisphere influenza season. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2025-2026-nh-influenza-season. Accessed on November 17, 2025.
- Singapore Communicable Disease Agency. Seasonal influenza. Available at www.cda.gov.sg/professionals/diseases/seasonal-influenza/. Accessed on November 17, 2025.
- Singapore Ministry of Health, HealthHub. Influenza Vaccine. Available at www.healthhub.sg/medication-devices-and-treatment/medications/influenza-vaccine. Accessed on November 17, 2025.
- Centers for Disease Control and Prevention. Influenza (Flu): Benefits of Getting a Flu Vaccine. https://www.cdc.gov/flu-vaccines-work/benefits/index.html. Accessed on November 17, 2025.
- De Gioia ER, Porqueddu A, Nebiaj O, Bianconi A, Conni A, Montalti M, Pandolfi P, Todeschini R, Fantini MP, Gori D. The Role of Needle Fear in Pediatric Flu Vaccine Hesitancy: A Cross-Sectional Study in Bologna Metropolitan Area. Vaccines (Basel). 2022 Aug 25;10(9):1388.
- Gasparini C, Acunzo M, Biuso A, Roncaglia S, Migliavacca F, Borriello CR, Bertolini C, Allen MR, Orenti A, Boracchi P, Zuccotti GV. Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020-21 season. Ital J Pediatr. 2021 Nov 13;47(1):225.
- Pérez Martín JJ, Zornoza Moreno M, Tornel Miñarro FI, Gómez Moreno MC, Valcárcel Gómez MDC, Pérez Martínez M. Influenza Vaccination in Children Younger than 5 Years in the Region of Murcia (Spain), a Comparative Analysis among Vaccinating and Non-Vaccinating Parents: Data from the FLUTETRA Study. Vaccines (Basel). 2024 Feb 13;12(2):192.
- Pérez-Martín JJ, Iofrío de Arce A, Zornoza-Moreno M. The Attitudes of Healthcare Professionals in an Autonomous Community in Spain towards Paediatric Influenza Vaccination. Vaccines (Basel). 2024 May 31;12(6):599.
